Resverlogix (FRA:RFS) Stock Based Compensation : €0.31 Mil (TTM As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Resverlogix Stock Based Compensation?

Resverlogix's Stock Based Compensation for the three months ended in Dec. 2023 was €0.17 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 was €0.31 Mil.

Resverlogix Stock Based Compensation Historical Data

The historical data trend for Resverlogix's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Stock Based Compensation Chart

Resverlogix Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Stock Based Compensation

Get a 7-Day Free Trial

3.37

4.67

2.32

2.26

1.15

Resverlogix Quarterly Data
	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Stock Based Compensation	Get a 7-Day Free Trial															0.67	0.07	-	0.14	0.17

Resverlogix Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.31 Mil.

Resverlogix Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Resverlogix's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Resverlogix (FRA:RFS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (FRA:RFS) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

RVXCF:USA RFS:Germany RVX:Canada

Address

4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1

Website

https://www.resverlogix.com

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Resverlogix (FRA:RFS) Headlines

No Headlines